Bakker, N. F. http://orcid.org/0000-0001-9203-9348
van Weely, S. F. E. http://orcid.org/0000-0001-8560-4687
Boonen, A. http://orcid.org/0000-0003-0682-9533
Vliet Vlieland, T. P. M. http://orcid.org/0000-0001-6322-3859
Knoop, J. http://orcid.org/0000-0002-2464-9037
Funding for this research was provided by:
ReumaNederland (2019-09-01)
Koninklijk Nederlands Genootschap voor Fysiotherapie (2019-09-01)
Article History
Received: 10 April 2024
Accepted: 5 June 2024
First Online: 20 June 2024
Declarations
:
: N.F. Bakker, S.F.E. van Weely, T.P.M. Vliet Vlieland and J. Knoop declare that they have no conflict of interest. A. Boonen received research grants from Abbvie and Lilly, and honoraria for lectures or consultation from Pfizer, Novartis, UCB, Abbvie and Galapagos; all to her department.
: Ethical approval to conduct the study was obtained on the 5th of May 2023 from the Medical Ethics Committee Leiden The Hague Delft (W.23.007). This study was conducted in agreement with the declaration of Helsinki and in compliance with the General Data Protection Regulations and the Dutch Medical Research Involving Human Subjects Act. All participants provided written informed consent for their participation.
: The data generated during this study will not be publicly available, but will be available upon reasonable request to the corresponding author.
: This study was selected by the European Alliance of Associations for Rheumatology (EULAR) Congress 2024 (12–15 June) for an oral abstract presentation. Online publication of the congress abstract will be provided by EULAR approximately two weeks prior to the congress.